Macular oedema and retinal vein occlusion | Guidance and guideline topic | NICE

Everything NICE has produced on the topic of macular oedema and retinal vein occlusion.

1 new

and

0 updated

products since January 2017.

Technology appraisal guidance

Aflibercept for treating diabetic macular oedema (TA346) July 2015
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409) September 2016
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305) February 2014
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229) July 2011
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349) July 2015
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301) November 2013
Ranibizumab for treating diabetic macular oedema (TA274) February 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283) May 2013

Interventional procedures guidance

Arteriovenous crossing sheathotomy for branch retinal vein occlusion (IPG334) March 2010

In development

Macular oedema (diabetic) - pegaptanib sodium [ID452] (GID-TAG280) TBC Technology appraisal guidance